Side effects

Metabolic syndrome from antipsychotics

April 11, 2026 10 min read

People with schizophrenia die, on average, 15 to 20 years earlier than the general population. A long-term commentary in The Lancet Psychiatry called this gap one of the largest mortality disparities in modern medicine. Most of the excess deaths are from cardiovascular disease, and most of that cardiovascular risk is metabolic. Antipsychotics are not the only contributor — smoking, sedentary lifestyle, poverty, fragmented care all matter — but they are a major driver of the metabolic side of the equation.

In one sentence

Metabolic syndrome is a cluster of cardiovascular risk factors — central obesity, elevated glucose, elevated triglycerides, low HDL, and elevated blood pressure — that occurs at high rates in people on antipsychotics, especially olanzapine and clozapine, and is the central modifiable contributor to early cardiovascular death in schizophrenia.

The criteria

The most widely used definition (NCEP ATP III) requires three or more of:

Roughly 30–50% of patients on long-term second-generation antipsychotics meet criteria for metabolic syndrome, compared with about 20–25% in the general adult US population.

How antipsychotics drive each component

Central obesity

Driven by histamine H1 and serotonin 5-HT2C antagonism (appetite up, satiety down) plus dopamine D2 effects on reward. Worst with olanzapine, clozapine, quetiapine. See our weight gain deep dive.

Triglyceride elevation

Olanzapine and clozapine raise triglycerides substantially, sometimes within weeks of starting and sometimes independent of weight gain. Quetiapine has a smaller but real effect. Aripiprazole, lurasidone, and ziprasidone are roughly neutral.

Low HDL

Closely tied to weight gain and inactivity. Improves with exercise and weight loss.

Hypertension

Indirect through weight gain and sleep apnea. Some antipsychotics (clozapine particularly) directly affect blood pressure regulation.

Glucose elevation

Covered in our diabetes deep dive.

The combined cardiovascular risk

Each component of metabolic syndrome independently raises cardiovascular risk, and the combination raises it more than the sum of the parts. People with metabolic syndrome have roughly twice the risk of cardiovascular disease and five times the risk of developing type 2 diabetes compared with people without it. Layered on top of the smoking rates and sedentary behaviour common in schizophrenia, the result is a population at very high cardiovascular risk by middle age.

Standard monitoring

The American Psychiatric Association, American Diabetes Association, and FDA-recommended schedule for any patient on a second-generation antipsychotic:

This monitoring schedule is the floor, not the ceiling. In real-world US practice it is implemented less than half the time.

Management strategy

1. Choose lower-risk agents when possible

For new starts, the metabolic profile of the antipsychotic should be part of the choice. Aripiprazole, lurasidone, ziprasidone, brexpiprazole, cariprazine, and lumateperone all have lower metabolic burden than olanzapine, clozapine, or quetiapine. The trade-off is efficacy and tolerability across other dimensions.

2. Treat each component aggressively

3. Coordinate with primary care

Many patients with serious mental illness fall between the cracks of psychiatry and primary care. Integrated care models (collaborative care, certified community behavioural health clinics) are partly built around this gap.

4. Address smoking

Smoking is the single largest contributor to cardiovascular mortality in schizophrenia. See our smoking cessation guide.

5. Build in physical activity

Even modest activity (walking 30 minutes a day) substantially improves several metabolic markers. Programmes that integrate exercise into mental health treatment have the best uptake.

Seek care if

Chest pain, shortness of breath on exertion, leg swelling, sudden weight gain, or symptoms of stroke (sudden weakness, slurred speech, vision change) on long-term antipsychotic treatment warrant urgent evaluation.

The 15-year mortality gap

The mortality gap between schizophrenia and the general population is one of the most striking inequities in medicine. It is also, in principle, one of the most addressable. A combination of better antipsychotic selection, proactive metformin and GLP-1 use, better statin prescribing, smoking cessation support, and integrated medical care could close a significant portion of the gap. Some health systems are achieving this; many are not.

The bottom line

Metabolic syndrome is the central modifiable health problem in schizophrenia. The treatment is not exotic. It is the standard of care that most patients in the general population get, applied consistently to a population that has historically not received it. Patients who advocate for their lab work, ask about statins, and bring up weight at appointments are the patients who tend to get the best care. Apps that surface labs and trends — including Frida — can help close the gap.

For more, see our metabolic syndrome overview, cardiovascular disease in schizophrenia, and lipid monitoring.


This article is for educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a qualified mental health professional. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.

Frequently asked questions

How often should my labs be drawn?
Baseline, at 12 weeks, then at least yearly. More often if there are abnormal values or significant weight gain. The schedule is the same regardless of which second-generation antipsychotic you are on.
Should I be on a statin?
Many patients with schizophrenia and elevated cardiovascular risk should be — and are not. The decision uses standard cardiovascular risk calculators. Discuss with your primary care physician.
Can I reverse metabolic syndrome?
Often yes. Weight loss of 5–10%, smoking cessation, and treatment of individual components can normalise risk markers and substantially reduce future cardiovascular events.
Is the metabolic risk worth the antipsychotic?
For most people with schizophrenia, the cardiovascular risk of untreated psychosis (through chaotic behaviour, suicide, and the toll of chronic stress) is also high. The aim is the lowest-risk antipsychotic that controls symptoms, paired with aggressive metabolic management.

Try Frida — your calm companion

Frida helps people living with schizophrenia track moods, manage medication, and build stability. 7-day free trial.

Get the app →